Thank you very much for that.
Through the chair to Monsieur Giroux, thank you for being here and thank you for your analysis.
We know that federal government spending is ballooning out of control. That does not mean that pharmacare is not important. We've heard now from Mr. Keon that there are not going to be any savings here, so this will continue to be an expense to the federal government and, of course, to taxpayers.
We don't have that much time, but maybe you could outline that expense, which is going to be a recurring expense to taxpayers, with respect to Bill C-64.